MedTrace Logo

Fosrenol Post-marketing Surveillance for Hemodialysis in Japan

NCT01419327 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 3267

Last updated 2020-05-20

No results posted yet for this study

Summary

This study is a regulatory post marketing surveillance in Japan, and it is a local prospective and observational study of patients in hemodialysis who received Fosrenol for hyperphosphatemia. The objective of this study is to assess safety and efficacy of using Fosrenol in clinical practice. A total 3,000 patients will be recruited and followed 5 years.

Conditions

  • Hyperphosphatemia

Interventions

DRUG

Lanthanum Carbonate (Fosrenol, BAY77-1931) - chewable tablet

Patients in hemodialysis who have received Fosrenol for hyperphosphatemia.

Sponsors & Collaborators

Principal Investigators

  • Bayer Study Director · Bayer

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-03-23
Primary Completion
2019-01-30
Completion
2019-05-28

Countries

  • Japan

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01419327 on ClinicalTrials.gov